Azenta Strengthens Life Sciences Presence with Acquisition of UK Biocentre for GBP 20.5 Million
- Azenta acquires UK Biocentre for GBP 20.5 million, enhancing its operational capabilities in the UK life sciences market.
- The acquisition aligns UK Biocentre’s expertise in sample management with Azenta's vision for advancing life sciences solutions.
- Azenta aims for organic revenue growth and improved EBITDA margins by 2027, strengthening its leadership in the life sciences sector.
Azenta Expands Life Sciences Solutions with Acquisition of UK Biocentre
Azenta, Inc., a leading player in life science solutions, announces the strategic acquisition of UK Biocentre Limited, a move that significantly bolsters its operational capabilities within the thriving UK market. With a total acquisition cost of GBP 20.5 million, which may increase to GBP 22.3 million based on performance milestones, this deal highlights Azenta's commitment to enhancing its end-to-end lifecycle solutions in one of the key hubs for life science research. The acquisition, finalized through Azenta's subsidiary Azenta UK Ltd, positions UK Biocentre as an operational centerpiece designed to support a diverse clientele, encompassing pharmaceutical companies, biotechnology firms, academic institutions, and public health organizations across Europe.
Founded in 2014, UK Biocentre specializes in critical areas such as sample management, storage, and high-throughput processing. With an impressive revenue of GBP 15.3 million for the year ending September 30, 2025, the company’s established capabilities align seamlessly with Azenta’s vision of advancing life sciences solutions. John Marotta, President and CEO of Azenta, emphasizes the strategic significance of the acquisition, viewing it as an opportunity to expand globally while introducing cutting-edge biorepository technologies such as the BioArc™ Ultra, capable of managing 16 million samples. This technological infusion not only enhances the operational efficacy of both organizations but also illustrates Azenta's intent to influence the evolution of the life sciences landscape markedly.
While the integration of UK Biocentre may lead to slight dilution of Azenta's 2026 Adjusted EBITDA margin, analysts project that it will ultimately foster organic revenue growth and improvements in EBITDA margins by 2027 and 2028. The marriage of these two entities is set to streamline critical workflows in the life sciences ecosystem, enhancing the quality and efficiency of scientific research and innovation. As UK Biocentre retains its identity, the symbiosis encapsulated in this acquisition is expected to establish Azenta as an even more formidable leader in the life sciences sector.
In related developments, the acquisition reaffirms Azenta's strategy to invest in high-growth areas of the life sciences market. With the increasing demand for advanced biorepository solutions, this move positions Azenta to leverage synergies in operations and client services across Europe. Furthermore, the ongoing commitment to scientific excellence showcases Azenta's dedication not only to growth but to the advancement of life sciences as a whole.